Cargando…
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Acute myeloid leukemia (AML) bears heterogeneous cells that can consequently offset killing by single-CAR-based therapy, which results in disease relapse. Leukemic stem cells (LSCs) associated with CD123 expression comprise a rare population that also plays an important role in disease progression a...
Autores principales: | Petrov, Jessica C., Wada, Masayuki, Pinz, Kevin G., Yan, Lulu E., Chen, Kevin H., Shuai, Xiao, Liu, Hua, Chen, Xi, Leung, Lai-Han, Salman, Huda, Hagag, Nabil, Liu, Fang, Jiang, Xun, Ma, Yupo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990523/ https://www.ncbi.nlm.nih.gov/pubmed/29515236 http://dx.doi.org/10.1038/s41375-018-0075-3 |
Ejemplares similares
-
Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
por: Salman, Huda, et al.
Publicado: (2019) -
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017) -
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022) -
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
por: Zhang, Wenli, et al.
Publicado: (2021) -
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)